Bannerji R et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol 2022;9(5):e327-39. Abstract
Bartlett NL et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2023;[Online ahead of print]. Abstract
Bartlett NL et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received >2 prior therapies: Updated results from a pivotal phase II study. ASH 2022;Abstract 610.
Budde LE et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. J Clin Oncol 2022;40(5):481-91. Abstract
Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2022;387(24):2220-31. Abstract
Falchi L et al. Subcutaneous epcoritamab with rituximab + lenalidomide in patients with relapsed or refractory follicular lymphoma: Phase 1/2 trial update. ASH 2022;Abstract 609.
Hutchings M et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1/2 study. Lancet 2021;398(10306):1157-69. Abstract
Hutchings M et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. J Clin Oncol 2021;39(18):1959-70. Abstract
Hutchings M et al. Glofitamab (glofit) in combination with polatuzumab vedotin (pola): Phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). ASH 2021;Abstract 525.
Jemaa S et al. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. Cancer Imaging 2022;22(1):39. Abstract
Kim TM et al. Odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) grade 1-3a: Results from a prespecified analysis of the pivotal phase II study ELM-2. ASH 2022;Abstract 949.
Kim W-S et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the pivotal phase II study ELM-2. ASH 2022;Abstract 444.
Lee DW et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019;25(4):625-38. Abstract
Morschhauser F et al. Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients with multiple relapsed or refractory (R/R) follicular lymphoma (FL). ASH 2021;Abstract 128.
Sam J et al. RG6333 (CD19-CD28), a CD19-targeted affinity-optimized CD28 bispecific antibody, enhances and prolongs the anti-tumor activity of glofitamab (CD20-TCB) in preclinical models. ASH 2022;Abstract P4259.
Thieblemont C et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin Oncol 2023;41(12):2238-47. Abstract